1. Home
  2. MBC vs AVLN Comparison

MBC vs AVLN Comparison

Compare MBC & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MasterBrand Inc.

MBC

MasterBrand Inc.

N/A

Current Price

$7.04

Market Cap

1.6B

Sector

Industrials

ML Signal

N/A

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$27.52

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBC
AVLN
Founded
1954
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2022
2026

Fundamental Metrics

Financial Performance
Metric
MBC
AVLN
Price
$7.04
$27.52
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$10.30
★ $62.25
AVG Volume (30 Days)
★ 2.7M
192.8K
Earning Date
11-03-2026
08-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $2,734,700,000.00
N/A
Revenue This Year
$27.96
N/A
Revenue Next Year
$19.09
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1.27
N/A
52 Week Low
$6.27
$24.90
52 Week High
$13.96
$40.17

Technical Indicators

Market Signals
Indicator
MBC
AVLN
Relative Strength Index (RSI) 35.62 35.91
Support Level $6.44 $25.86
Resistance Level $7.45 $30.45
Average True Range (ATR) 0.37 2.25
MACD 0.04 -0.56
Stochastic Oscillator 47.03 14.12

Price Performance

Historical Comparison
MBC
AVLN

About MBC MasterBrand Inc.

MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: